Modulation of Type 1 Diabetes Susceptibility Through the Use of Probiotics

NCT03423589 | Completed

• 1 other identifier: 1171017
• Study Type: interventional
• Target: 30
• Locations: 1 country
• Sites: 1

Brief Summary

Investigators aim to further the understanding of environmental factors that underlie the progression to Type 1 diabetes (T1D). Dysbiosis, defined as alterations in intestinal microbiota composition and function, has been hypothesized to increase the risk of developing T1D in those with genetic susceptibility. Dysbiosis may result from modern dietary habits, such as broad consumption of the highly processed Western Diet, or by widespread use of antibiotics. Here, investigators propose to examine the impact of dysbiosis on the endogenous innate inflammation known to exist within families affected by T1D and if probiotic supplementation may beneficially modulate this inflammatory state. Participants will be asked to take the probiotic VSL#3 daily for six weeks. Stool and blood samples will be analyzed before and after the six week course of probiotics.

Conditions

Type1diabetes; Type1 Diabetes Mellitus

Keywords

Siblings

Outcome Measures

Primary Outcomes (1)

• Alterations in Plasma-Induced Transcriptional Analysis

  Examine the probiotic-induced alterations in the plasma-induced transcriptional analysis

  2 years (study duration)

Secondary Outcomes (1)

• Intestinal Microbiota

  2 years (study duration)

Study Arms (1)

VSL#3

EXPERIMENTAL

Participants will be given the probiotic supplement VSL#3, a commercially available product. VSL#3 is taken by mouth, either once or twice daily, and is dispensed in sachets, each containing 450 billion colony forming units of bacterial strains. Participants will undergo a screening visit. They will be asked to provide a stool sample by the next visit. Within 3 weeks they will return with a stool sample and receive the VSL#3 sachets as well as another stool collection kit. After 6 weeks of taking VSL#3, they will return for their final visit, with their stool sample. Blood will be drawn at the second and third visits.

Dietary Supplement: VSL#3

Interventions

VSL#3 DIETARY_SUPPLEMENT

VSL#3 is a commercially available probiotic supplement manufactured and distributed by Alfasigma USA, Inc of Covington, Louisiana, USA. As with other probiotics, VSL#3 is considered a supplement and is not FDA-approved or regulated. VSL#3 contains eight probiotic strains: bifidobacteria (B. longum, B. infantis, and B. breve), lactobacilli (L. acidophilus, L. casei, L. bulgaricus, and L. plantarum) and Strepococcus thermophiles.

VSL#3

Eligibility Criteria

• Age: 5 Years - 17 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Child (0-17)

You may qualify if:

• Males and females 5-17 years of age
• Full-sibling of an individual with a clinical diagnosis of Type 1 diabetes
• Treatment naïve of any immunomodulatory agent
• Naïve of any probiotic supplement within the past 12 months

You may not qualify if:

• Presence of severe/active disease that interferes with dietary intake
• Chronic use of medications known to affect gastrointestinal function, such as stool softeners or laxatives
• Diagnosis of celiac disease and/or following a gluten-free diet
• Presence of significant and sustained gastrointestinal symptoms within the prior 6 weeks (e.g., severe abdominal pain, worsening constipation, diarrhea, or recurrent nausea +/- vomiting)
• Chronic inflammatory or autoimmune disease with the exception of well-controlled hypothyroidism or intermittent or mild persistent asthma not requiring the use of daily inhaled steroids
• Use of any medications that could affect intestinal microbiota within the previous 3 months (e.g., antibiotics, prebiotics, or probiotics)
• Any condition that, in the investigator's opinion, may compromise study participation or may confound the interpretation of the study results
• Female participants of child-bearing age must not be pregnant

Sponsors & Collaborators

• Medical College of Wisconsin: lead

Study Sites (1)

Medical College of Wisconsin

Milwaukee, Wisconsin, 53226, United States

Location

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: OTHER
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: MD

Study Record Dates

• First Submitted: January 31, 2018
• First Posted: February 6, 2018
• Study Start: April 23, 2018
• Primary Completion: December 18, 2018
• Study Completion: December 31, 2018
• Last Updated: July 22, 2024

Record last verified: 2024-07

Locations

US (1)